A major problem with the use of serum prostate-specific antigen (PSA) in predicting prostate cancer risk is the considerable variability of such measurements. Cramer et al. identified a set of singlenucleotide polymorphisms (SNPs) in the upstream regulatory region of the PSA gene that were each associated with increased promoter activity and serum PSA, further suggesting that genotyping these SNPs could be useful in improving the predictive value of PSA screening. In order to replicate this finding, DNA samples from 475 African-American men were genotyped for the same SNPs and no association was observed with either serum PSA level or prostate cancer diagnosis.
Introduction
Prostate cancer is the most common cancer diagnosed among men in the US with an expected 232 000 new cases in 2005. 1 In addition to increasing age and family history, race is one of the most important recognized risk factors for the disease. 2 African-American men have an approximately 1.6-fold greater chance of being diagnosed with prostate cancer compared to Caucasian men and a 2.4-fold greater chance of dying from the disease. 1 There are multiple variables that likely contribute to the racial disparity in both incidence and mortality including genetic, environmental, and sociological factors.
Prostate-specific antigen (PSA) was first proposed as a serum marker for the early detection of prostate cancer nearly 29 years ago. 3 PSA is a serine protease that is expressed in both normal prostate epithelium as well as prostate cancer. Although serum PSA elevations greater than 4.0 ng/ml are associated with prostate cancer, the positive predictive value (PPV) of a serum PSA value between 4.0 and 10 ng/ml is only 20-30%, although the PPV rises to 40-70% for serum PSA values greater than 10 ng/ml. 4 A recent analysis of data from the Prostate Cancer Prevention Trial (PCPT) has demonstrated that prostate cancer can also be diagnosed in men with PSA values generally considered to be in the normal range. In the PCPT, approximately 15% of men with normal digital rectal examinations and PSA values consistently under 4.0 ng/ml over a period of 7 years were determined to have prostate cancer on biopsies performed at the end of the study. 5 Clearly, more research needs to be done to improve the use of serum PSA as a screening test for prostate cancer in asymptomatic men.
Transcriptional regulation of the PSA gene is mediated through binding of the androgen receptor to regions of the promoter containing androgen response elements (AREs). 6 In 2003, Cramer et al. 7 reported that specific germline genetic polymorphisms in the promoter region of the PSA gene were associated with higher serum PSA levels among 409 Caucasian male subjects (mean age 63.7 years). They further suggested that these polymorphisms may be useful in refining the recommendations for use of serum PSA levels for prostate cancer screening. Given the importance of prostate cancer in AfricanAmerican men, we set out to explore the potential association between selected functional single-nucleotide polymorphisms (SNPs) in the PSA gene with serum PSA levels and prostate cancer risk using samples from the Flint Men's Health Study.
Materials and methods
The Flint Men's Health Study (FMHS) is a communitybased study of prostate cancer in African-American men between the ages of 40 and 79 years. In 1996, 730 men were recruited to participate in the study from a probability sample residing in the city of Flint and surrounding communities in Genesee County, Michigan. Subjects completed a detailed in-home interview that collected information on sociodemographics, potential risk factors for prostate cancer, and a complete medical history. Subjects were also asked to participate in a clinical examination which included measurement of serum PSA (free and total) and a comprehensive urologic examination. Exam participants were asked to refrain from sexual activity for at least 24 h prior to the blood draw and all venipuncture was performed before referral for digital rectal exam as both may cause transitory increases in PSA level. Men with an elevated total PSA (X4.0 ng/ml) or an abnormal digital rectal exam were referred for prostate biopsy. Of the 730 men who completed the initial interview, 379 participated in the clinical exam. A total of 10 subjects were diagnosed with prostate cancer as a consequence of the protocol which resulted in a final control sample of 369 men. Attempts were made to follow the study participants and in the 5 years after control recruitment, an additional 18 control men were diagnosed with prostate cancer. Four controls with a total PSA level greater than 9.0 ng/ml were also excluded from the analysis following the analysis plan of Cramer et al. 7 A sufficient DNA sample was available for genotyping on 339 of the remaining controls.
Cases were recruited from the same community from 1999 to July 2002. Men who were between the ages of 40 and 79 years at the time of prostate cancer diagnosis (between 1995 and 2002) were eligible to participate in the study. Cases also completed a detailed epidemiologic interview and provided a blood sample. Medical records were reviewed to extract information related to prostate cancer diagnosis including clinical and pathologic stage, Gleason grade, prediagnostic PSA, and treatment. A total of 136 cases were ultimately recruited to participate in the study. Informed consent was obtained from all study participants and the research protocol has been approved by the Institutional Review Board of the University of Michigan. For both cases and controls, genomic DNA was isolated from whole blood using the Puregene DNA Purification Kit (Gentra Systems, Minneapolis, MN, USA).
SNP selection and genotyping methods
Three SNPs in the 5 0 promoter region of the PSA gene were selected: -4643 A/G (rs925013), -5412 T/C (rs2739448), and -5429 T/G (rs2569733). Each of these SNPs were present at greater than 5% frequency in a Caucasian sample and also were shown to be associated with PSA levels. 7 For the -4643 A/G (rs925013) SNP, Assays on Demand SNP genotyping products (Applied Biosystems, Foster City, CA, USA) were used. These consist of a 20 Â mixture of PCR primers and dye labeled TaqMan MGB probes designed to genotype a specific SNP within a given sequence. PCR reactions were performed in a 384-well plate format with 2.25 ml of genomic DNA (4 ng/ml), 0.25 ml 20 Â SNP Genotyping Assay Mix, 1.0 ml 5Â Real Time Ready Mastermix (Qbiogene, Montreal, Canada), and 1.5 ml dH 2 0 for a total reaction volume of 5.0 ml. For the remaining two SNPSs, Assays by Design SNP genotyping products (Applied Biosystems, Foster City, CA, USA) were employed. These assays were custom-designed and produced based upon target sequence submission by using Assay by Design File Builder (Applied Biosystems, Foster City, CA, USA). PCR reactions were performed in a 384-well plate format with 2.375 ml of genomic DNA (4 ng/ml), 0.125 ml 40 Â SNP Genotyping Assay Mix, 1.0 ml 5Â Real Time Ready Mastermix (Qbiogene, Montreal, Canada), and 1.5 ml dH 2 0 for a total reaction volume of 5.0 ml. Assays were optimized to use a universal thermal cycling protocol with an initial hold at 951C for 10 min followed by 40 cycles at 921C for 15 s and a combined annealing extension step of 601C for 1 min. Allelic discrimination was then performed on ABI Prism 7900 HT Sequence Detection System and analyzed using SDS 2.1 software (Applied Biosystems, Foster City, CA, USA). At least 23% of the sample set was duplicated on this platform for verification of results.
Validation of results
Validation by restriction enzyme digest was performed on 15% of the sample set for the -4643 A/G (rs925013) SNP. PCR primers (5 0 CAGGGATTATCTTCAGCACTTA-CA 3 0 , 5 0 ACTGGCCAGCTGGGAATAGAGATA 3 0 ) were designed using Primer Select software (DNASTAR Inc., Madison, WI, USA) and purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Each reaction contained 5.0 ml 10 Â PCR buffer, 1.0 ml 50 mM MgCl 2 , 1.0 ml 10 mM dNTPs, 5.0 ml each of the two PCR primers at 5 mM, 2.0 ml genomic DNA at 20 ng/ml, 0.5 ml Platinum Taq Polymerase (Invitrogen Life Technologies), and 30.5 ml ddH 2 0 for a total reaction volume of 50.0 ml. PCR products were digested using 40.0 ml PCR product, 2.0 ml NcoI restriction enzyme, 5.0 ml 10 Â NE Buffer #4 (New England Biolabs Inc., Beverly, MA, USA), and 3.0 ml ddH 2 O for a total reaction volume of 50.0 ml. Samples were placed in a 371C water bath and allowed to incubate for at least 4 h. Digested products were analyzed on 3% agarose gels.
Validation by direct sequencing was performed on 14% of the sample set for the 5412 T/C (rs2739448), and -5429 T/G (rs2569733) SNPs. For direct sequence analysis, PCR products were purified using Montage PCR Centrifugal Filter Devices (Millipore, Billerica, MA, USA). Cycle sequencing was performed in the forward direction using Big Dye Terminator Chemistries (Applied Biosystems, Foster City, CA, USA). Cycle sequencing reactions were purified using Performa DTR Gel Filtration Cartridges (Edge Biosystems, Gaithersburg, MD, USA) and were sequenced using an ABI 3100 Genetic Analyzer.
Statistical analysis
For each SNP, the observed genotype distribution was tested for consistency with Hardy-Weinberg equilibrium expectations using Pearson's w 2 test (SAS version 8.2, Cary NC, USA). Lewontin's D 0 statistic was calculated to
Polymorphisms in prostate-specific antigen gene and serum PSA JL Beebe-Dimmer et al estimate the strength of linkage disequilibrium between all possible pair-wise combinations of SNPs using the computer software GOLD (www.sph.umich.edu/csg/ abecasis/GOLD/index.html). 8 PSA levels in our population were not normally distributed after adjustment for age at clinical exam and genotype. Similar to Cramer et al., a log base-10 (log10) transformation was performed on the PSA levels in order to satisfy distributional assumptions. Analysis of variance was performed to evaluate differences in mean values for log10 total PSA, log10-free PSA, and ratio of free to total PSA levels by genotype for each SNP adjusting for age. Since homozygosity for the least prevalent allele was rare in our study population (o1%), the reported P-values were calculated based on tests comparing the outcome measurements for heterozygotes and homozygotes for the least prevalent allele to homozygotes for the most prevalent allele for each SNP. The least-square means for log10 total, log10-free PSA, and the ratio of free to total PSA were calculated for each genotype. Logistic regression models were used to test whether each SNP was associated with prostate cancer. Finally, haplotype frequencies, the association between haplotypes and the PSA outcome variables adjusted for age, and the association between haplotypes and prostate cancer were evaluated using the program Haplo.Stat. 9 
Results
The genotype distributions for each of the three SNPs were found to be consistent with expected HardyWeinberg equilibrium proportions in both the case and control samples (data not shown). The observed genotype frequencies of the selected PSA promoter SNPs among the FMHS 339 control and 136 case participants are reported in Table 1 . Men who were homozygous for the less prevalent allele were rare in this study population. All three SNPs were in near perfect linkage disequilibrium (Po0.0001 for all pairs), with pair-wise D 0 estimates of 0.95, 0.97, and 0.99 for the pairings (-4643, -5412), (-4643, -5429) and (-5412, -5429), respectively. No significant differences in the frequencies of each of the three SNPs were observed between prostate cancer cases and controls (Table 2 ). Just one prostate cancer case (0.7%) and one control individual (0.3%) were determined to be homozygous for the least prevalent allele for all three SNPs. Approximately 15-16 % of cases and 18-19% of controls were heterozygotes for the three SNPs. Consistent with the analyses of PSA levels, statistical significance estimates for the case/control analyses (Table 2 ) reflect the results of single degree-of-freedom tests comparing the odds of being a case for individuals heterozygous or homozygous for the least prevalent allele to individuals with the most frequent allele. The case/control haplotype analyses failed to detect significant differences in haplotype frequencies between cases and controls (global score statistic ¼ 0.81, P ¼ 0.66; data not shown).
Age-specific PSA ranges for control subjects participating in the FMHS have been previously reported. 10 No associations were observed between different genotypes in selected SNPs in the promoter region of the PSA gene with log10 total PSA levels, log10 free PSA levels, or the ratio of free to total PSA (Table 3) . Men with the GT genotype at -5429 SNP had similar total PSA levels compared to men with the TT genotype. Likewise, total PSA levels among men with the AG genotype in -5412 SNP were similar to men with the AA genotype. Since SNPs -4643 and -5412 were in almost perfect linkage disequilibrium, serum free and total PSA levels for each genotype in -4643 were nearly identical to those observed at SNP -5412. Of note, the individual who was homozygous for the rare allele at all three SNPs in this study had a higher PSA than the mean values for each of the other genotypes.
In order to examine whether specific combinations of allelic variants were associated with serum PSA levels, we performed haplotype-based association analyses ( Table 4 ). The frequency of haplotypes -5429T/-5412T/ 4643A and -5429G/-5412C/4643G were approximately 90 and 9%, respectively. No significant differences in log10 total PSA, log10 free PSA, or ratio of free to total PSA levels were observed between the three selected haplotypes.
Discussion
Cramer et al. 7 reported that three polymorphisms (-4643 A/G, -5412 T/C, and -5429 T/G) located at the far 5 0 upstream region of the promoter were significantly Polymorphisms in prostate-specific antigen gene and serum PSA JL Beebe-Dimmer et al associated with increased PSA levels using samples from Caucasian asbestos workers participating in a study of asbestos exposure and lung disease. The three SNPs were moderately prevalent in the population, with approximately 21-23% of men carrying the variant allele, and the SNPs were shown to be in strong linkage disequilibrium. Further analysis revealed that the -5429T/-5412T/-4643A haplotype, which occurred in 77% of the population, was associated with significantly lower serum PSA levels (Po0.001), while the -5429G/-5412C/-4643G haplotype occurring in 20% of the population was associated with higher PSA (P ¼ 0.009). In our study of a cohort of 339 African-American men between the ages of 40 and 79 years with PSA levels less than 9 ng/ml and no known diagnosis of prostate cancer, one haplotype (-5429T/-5412T/-4643A) was detected in 90% of the population and no relationship was detected between any haplotype and PSA level. 7 A number of studies have examined associations between genetic polymorphisms in the PSA gene, PSA levels, and prostate cancer risk. The PSA gene is a member of a family of 15 kallikrien genes clustered on chromosome 19q13.3-13.4.
11 Activity of the gene and expression of PSA is largely mediated through androgen responsive elements (AREs) located in the proximal promoter and 5 0 upstream enhancer. 6 Rao et al. 12 initially identified a single SNP within the region, a G/A substitution at À158 bp in the ARE I. It was subsequently reported that possession of the A allele was associated with increased serum PSA. 13, 14 However, the associations between the ARE I polymorphism with either PSA levels have not been consistent. [15] [16] [17] In a study of 518 men, Xu et al. reported no association between polymorphisms in ARE I and PSA levels. The authors suggest that possession of the G allele was associated with increased serum PSA among white men participating in their study, but also note that the highest serum PSA levels among black subjects were observed with the AA genotype. Furthermore, Rao et al. found no difference in serum PSA associated with the ARE I genotype (P ¼ 0.79). Both studies also examined the relationship between the ARE I genotype and polymorphisms in the androgen receptor gene and with PSA and observed no significant interaction in contrast to other reports. Polymorphisms in prostate-specific antigen gene and serum PSA JL Beebe-Dimmer et al
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The A allele at nucleotide position À158 has also been associated with prostate cancer risk in some studies, 14, 19 but not in all. 17 It is worth noting that some studies report that overall risk appears higher among men with the AA genotype, and there are other publications showing that the GG genotype is associated with development of advanced cancer. Xue et al. 18 observed a higher frequency of the GG PSA genotype among men with advanced prostate cancer (evidence of extraprostatic extension, invasion into surrounding tissue, nodal involvement, and/or metastatic disease) (OR ¼ 2.90; 95% CI ¼ 1.24-6.78). A study conducted in China recently reported the GG PSA genotype was associated both with prostate cancer risk overall (OR ¼ 2.27; P ¼ 0.008) and also with greater tumor volume and higher pathologic stage. 20 The GG genotype has also been observed more frequently among patients with a Gleason grade of 7 and higher. 19 The inconsistency in reported observations with respect to the À158 SNP in ARE I of the PSA gene are due in part to differences in the racial and ethnic composition of eligible study subjects. For example, the GG genotype at the À158 SNP is seen in 24% of African-Americans men, 13 29% of Non-Hispanic white men, 13 61% of Japanese men, 17 and 62% of Chinese men. 20 This fact, coupled with relatively sample size of the study populations, may contribute to the differing results between the ARE I SNP and both serum PSA level as well as prostate cancer diagnosis. Importantly, the À158 SNP has been shown using in vitro assays to have no effect on PSA gene promoter activity. 12 Using samples from a community-based study of African-American men from the FMHS, we elected to focus on the three PSA promoter SNPs (-4643 A/G, -5412 T/C, and -5429 T/G) upstream from the À158 A/G SNP discussed above. Using transfection assays into the human prostate cancer cell line LNCaP, luciferase reporter constructs containing either the G substitution at À4643 (along with a T at both position À5429 and À5412) or a combination of the C substitution at position À5412 and the G substitution at position À5429 (along with an A at position À4642) each showed more potent promoter activity using transient compared to constructs with the alternative nucleotide at the respective polymorphic site. 7 In addition to the in vitro evidence that these variants were functionally important, all three SNPs were shown by Cramer et al. to be in tight linkage disequilibrium with the À158 ARE I polymorphisms. However, in our study, we were unable to detect evidence that these genetic polymorphisms were associated with either total or free serum PSA levels. The observed frequency of the functional alleles of interest in our study population were approximately half (B10 vs B20%) of that reported among white men in the Cramer study.
There are distinct differences in the design of each of these studies that might account for some of the inconsistency between findings. The primary aim of the investigation conducted by Cramer and co-workers was to examine the relationship between occupational asbestos exposure and lung disease among asbestos-exposed workers. Serum PSA was drawn initially to examine the relationship between asbestos exposure and prostate cancer risk and it is unknown if blood was drawn at the same time of the day for each participant. Evidence suggests that there is significant diurnal variability in PSA levels among men with and without prostate disease and the variation is unpredictable. 21, 22 The FMHS protocol required blood draws for all participants between 0900 and 1100 hours to reduce the impact of temporal variability of results. Furthermore, because the participants of Cramer et al. were selected for inclusion into the study based upon their occupation, it is possible that some exposure unique to their occupation, whether asbestos or another substance, might alter their PSA levels. However, it is also possible that the findings represent real racial/ethnic differences in the prevalence and importance of these SNPs in influencing PSA and the utility of these SNPs in predicting PSA and/or prostate cancer risk in Caucasian populations may be greater than in African Americans. Further study is required before any firm conclusions can be drawn with respect to these SNPs in any population.
There are limitations in our study which must be discussed in the context of our findings. First, we have a relatively small sample size which places some limitations on our statistical power to detect small effects due to genotype. Specifically, given our observed genotype frequencies and standard errors in log10 PSA measurements by group, we would have less than 80% power to detect a significant difference (using a ¼ 0.05) in PSA level means between genotypes that is smaller than approximately 15%. Second, we did not genotype all SNPs within the PSA gene, therefore other SNPs within the gene may be associated with PSA serum levels in African Americans. We chose to focus on three functionally important SNPs in the promoter region in the PSA gene that have been reported previously as being associated with serum PSA levels. Third, among the control subjects, less than 60% of men who completed the initial epidemiologic survey participated in the blood draw and clinical examination. An analysis of the potential selection bias as a result of response rate in this population revealed that although men who participated in all phases of the study were younger, more likely to have a family history of prostate cancer and were likely to report the presence of urologic symptoms than nonparticipants, greater participation in the clinical phase of the study did not bias the estimated age-specific reference ranges for total PSA concentrations. 23 Based on these analyses, we have no reason to believe that participants and nonparticipants differ systematically with respect to their genetic background.
In conclusion, our analysis of 475 African-American men with and without prostate cancer does not suggest that SNPs in the 5 0 upstream promoter region of the PSA gene influence free or total serum PSA level. Moreover, we did not demonstrate an association between these polymorphisms and prostate cancer risk. The observed prevalence of the alleles of interest in this communitybased study were substantially lower than the prevalence reported in a study of Caucasian men published by Cramer et al. Given the strong linkage disequilibrium between these SNPs as observed in both studies, it will be difficult to establish the independent contribution of each polymorphism. Clearly, additional studies are needed to determine the importance of these SNPs as predictors of serum PSA levels and/or whether these polymorphisms are associated with prostate cancer risk. While enhanced methods for detecting prostate cancer in asymptomatic men are clearly required, it is not clear Polymorphisms in prostate-specific antigen gene and serum PSA JL Beebe-Dimmer et al that PSA promoter polymorphisms will be able to provide much improvement in the current standard of care using serum measurements of PSA.
